Science & Research
Dr. Eliaz and his team partner with renowned institutes including Harvard, Columbia, and others to investigate integrative approaches in the treatment of cancer and chronic conditions. In addition, many of Dr. Eliaz’s unique preparations have been studied independently by third-party groups, with peer-reviewed results demonstrating unparalleled benefits against cancer, fibrotic diseases and more.
The unique form of Modified Citrus Pectin developed by Dr. Eliaz is recognized as the only commercially available galectin-3 blocker, substantiated by more than 40 published studies in cancer, cardiovascular disease, chronic kidney disease, and other pro-inflammatory, degenerative conditions.
Summaries below include links to research abstracts.
-
Galectin-3 Research
2020 Review: A Potential Role for Galectin-3 Inhibitors in the... -
Modified Citrus Pectin Research
2020 Preclinical Study: Modified Citrus Pectin Targets Hypoxia-Induced Galectin-3 in... -
Heavy Metal Chelation and Detoxification Research
2020 Clinical Study: Polycyclic Aromatic Hydrocarbon Exposure and Cytokine Storms... -
Medicinal Mushroom Research
2020 Preclinical Study: Antibiofilm and Antimicrobial Activities of Five Mushrooms... -
Honokiol Research
2020 Preclinical Study: Honokiol Ameliorates Pulmonary Fibrosis 2019 Preclinical Study: Antidepressant-like... -
Tibetan Herbal Formula Research
2016 Clinical Review: Tibetan Herbal Preparation Reduces Pain and Increases... -
Breast Cancer Research
2017 Preclinical Study: Polybotanical Breast Formula Enhances Tamoxifen in Estrogen... -
Prostate Cancer Research
2019 Clinical Study Updated Results: Modified Citrus Pectin Halts Biochemically-Relapsed... -
Cardiovascular and Circulatory Health Research
2019 Preclinical Study: Modified Citrus Pectin Improves Ischemic Heart Failure...